Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Diazepam in the Elderly: Looking Back, Ahead, and at the Evidence.

Tytuł :
Diazepam in the Elderly: Looking Back, Ahead, and at the Evidence.
Autorzy :
Greenblatt DJ; From Tufts University School of Medicine, Boston, MA.
Harmatz JS
Shader RI
Pokaż więcej
Źródło :
Journal of clinical psychopharmacology [J Clin Psychopharmacol] 2020 May/Jun; Vol. 40 (3), pp. 215-219.
Typ publikacji :
Editorial
Język :
English
Imprint Name(s) :
Publication: Baltimore Md : Williams And Wilkins
Original Publication: Baltimore, Md. : Williams & Wilkins, [c1981-
MeSH Terms :
Central Nervous System Sensitization*
Anxiety Disorders/*drug therapy
Diazepam/*adverse effects
Diazepam/*therapeutic use
Aged ; Aged, 80 and over ; Diazepam/pharmacokinetics ; Female ; Forecasting ; Humans ; Male
References :
Sternbach LH. The benzodiazepine story. Prog Drug Res. 1978;22:229–266.
Greenblatt DJ, Shader RI. Benzodiazepines in Clinical Practice. New York, NY: Raven Press; 1994.
Wick JY. The history of benzodiazepines. Consult Pharm. 2013;28:538–548.
Lopez-Munoz F, Alamo C, Garcia-Garcia P. The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: half a century of anxiolytic drugs. J Anxiety Disord. 2011;25:554–562.
Greenblatt DJ, Shader RI. Benzodiazepines. N Engl J Med. 1974;291:1011–1015, 1239-1243.
Greenblatt DJ, Shader RI, Abernethy DR. Current status of benzodiazepines. N Engl J Med. 1983;309:354–358, 410-416.
Greenblatt DJ, Shader RI. Pharmacokinetics of antianxiety agents. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:1377–1384.
Gorevski E, Bian B, Kelton CM, et al. Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991-2009. Ann Pharmacother. 2012;46:503–512.
Blackwell B. Psychotropic drugs in use today. The role of diazepam in medical practice. JAMA. 1973;225:1637–1641.
Greenblatt DJ, Shader RI, Koch-Weser J. Psychotropic drug use in the Boston area. Arch Gen Psychiatry. 1975;32:518–521.
Hollister LE. A look at the issues. Psychosomatics. 1980;21(Oct. suppl):4–8.
Greenblatt DJ, Shader RI. Pharmacotherapy of anxiety with benzodiazepines and β-adrenergic blockers. In: Lipton MA, DiMascio A, Killam KF, eds. Psychopharmacology: A Generation of Progress. New York, NY: Raven Press; 1978:1381–1389.
Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993;328:1398–1405.
Hollister LE, Muller-Oerlinghausen B, Rickels K, et al. Clinical uses of benzodiazepines. J Clin Psychopharmacol. 1993;13(6 suppl 1):1S–169S.
Nardi AE, Cosci F, Balon R, et al. The prescription of benzodiazepines for panic disorder: time for an evidence-based educational approach. J Clin Psychopharmacol. 2018;38:283–285.
Balon R, Starcevic V. Role of benzodiazepines in anxiety disorders. Adv Exp Med Biol. 2020;1191:367–388.
Matthew H, Proudfoot AT, Aitken RC, et al. Nitrazepam—a safe hypnotic. Br Med J. 1969;3:23–25.
Barraclough BM. Are there safer hypnotics than barbiturates? Lancet 1974; 1(7846): 57–58.
Unreasonable profit. Lancet 1973; 1(7808): 867.
Benzodiazepines: use, overuse, misuse, abuse? Lancet 1973; 1(7812): 1101–1102.
Lader M. Benzodiazepines—the opium of the masses? Neuroscience. 1978;3:159–165.
Greenblatt DJ, Shader RI. Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug Metab Rev. 1978;8:13–28.
Miller NS, Gold MS. Benzodiazepines: reconsidered. Adv Alcohol Subst Abuse. 1990;8(3-4):67–84.
Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376:1147–1157.
Salzman C, Shader RI. Not again: benzodiazepines once more under attack. J Clin Psychopharmacol. 2015;35:493–495.
Juergens SM. Problems with benzodiazepines in elderly patients. Mayo Clin Proc. 1993;68:818–820.
Maust DT, Kales HC, Wiechers IR, et al. No end in sight: benzodiazepine use in older adults in the United States. J Am Geriatr Soc. 2016;64:2546–2553.
Marra EM, Mazer-Amirshahi M, Brooks G, et al. Benzodiazepine prescribing in older adults in U.S. ambulatory clinics and emergency departments (2001-10). J Am Geriatr Soc. 2015;63:2074–2081.
Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiat. 2015;72:136–142.
Agarwal SD, Landon BE. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open. 2019;2:e187399.
Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations. Clin Pharmacokinet. 1991;21:165–177, 262-273.
Davies EA, O'Mahony MS. Adverse drug reactions in special populations — the elderly. Br J Clin Pharmacol. 2015;80:796–807.
American Geriatrics Society 2019 Updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67:674–694.
Parekh N, Ali K, Davies JG, et al. Do the 2015 Beers Criteria predict medication-related harm in older adults? Analysis from a multicentre prospective study in the United Kingdom. Pharmacoepidemiol Drug Saf. 2019;28:1464–1469.
Salzman C, Shader RI, Greenblatt DJ, et al. Long v short half-life benzodiazepines in the elderly. Kinetics and clinical effects of diazepam and oxazepam. Arch Gen Psychiatry. 1983;40:293–297.
Herings RM, Stricker BH, de Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med. 1995;155:1801–1807.
Wang PS, Bohn RL, Glynn RJ, et al. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry. 2001;158:892–898.
Gray SL, LaCroix AZ, Hanlon JT, et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc. 2006;54:224–230.
de Vries OJ, Peeters G, Elders P, et al. The elimination half-life of benzodiazepines and fall risk: two prospective observational studies. Age Ageing. 2013;42:764–770.
Greenblatt DJ, Divoll M, Abernethy DR, et al. Physiologic changes in old age: relation to altered drug disposition. J Am Geriatr Soc. 1982;30(Nov. suppl): s6–s10.
Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. New England Journal of Medicine. 1982;306:1081–1088.
Klotz U, Avant GR, Hoyumpa A, et al. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975;55:347–359.
MacLeod SM, Giles HG, Bengert B, et al. Age- and gender-related differences in diazepam pharmacokinetics. J Clin Pharmacol. 1979;19:15–19.
Kanto J, Mäenpää M, Mäntylä R, et al. Effect of age on the pharmacokinetics of diazepam given in conjunction with spinal anesthesia. Anesthesiology. 1979;51:154–159.
Macklon AF, Barton M, James O, et al. The effect of age on the pharmacokinetics of diazepam. Clin Sci (Lond). 1980;59:479–483.
Greenblatt DJ, Allen MD, Harmatz JS, et al. Diazepam disposition determinants. Clin Pharmacol Ther. 1980;27:301–312.
Ochs HR, Greenblatt DJ, Divoll M, et al. Diazepam kinetics in relation to age and sex. Pharmacology. 1981;23:24–30.
Herman RJ, Wilkinson GR. Disposition of diazepam in young and elderly subjects after acute and chronic dosing. Br J Clin Pharmacol. 1996;42:147–155.
Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev. 1987;39:1–47.
Greenblatt DJ. Basic pharmacokinetic principles and their application to psychotropic drugs. J Clin Psychiatry. 1993;54(Sept. suppl): 8–13.
Greenblatt DJ, Koch-Weser J. Clinical pharmacokinetics. New England Journal of Medicine. 1975;293:702–705, 964-970.
Greenblatt DJ, Abourjaily PN. Pharmacokinetics and pharmacodynamics for medical students: a proposed course outline. J Clin Pharmacol. 2016;56:1180–1195.
Greenblatt DJ, He P, von Moltke LL, et al. The CYP3 family. In: Ioannides C, ed. Cytochrome P450: Role in the Metabolism and Toxicology of Drugs and Other Xenobiotics. Cambridge, UK: Royal Society of Chemistry; 2008:354–383.
Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44:33–60.
von Moltke LL, Greenblatt DJ. Pharmacokinetics of psychotropic drugs in the elderly. Annual Review of Gerontology and Geriatrics. 1999;19:53–71.
Greenblatt DJ, Sellers EM, Koch-Weser J. Importance of protein binding for the interpretation of serum or plasma drug concentrations. J Clin Pharmacol. 1982;22:259–263.
Butler JM. Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet. 2008;47:297–321.
Greenblatt DJ, Allen MD, Shader RI. Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther. 1977;21:355–361.
Giles HG, MacLeod SM, Wright JR, et al. Influence of age and previous use of diazepam dosage required for endoscopy. Can Med Assoc J. 1978;118:513–514.
Reidenberg MM, Levy M, Warner H. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther. 1978;23:371–374.
Greenblatt DJ, Allen MD. Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. Br J Clin Pharmacol. 1978;5:407–413.
Cook PJ, Flanagan R, James IM. Diazepam tolerance: effect of age, regular sedation, and alcohol. Br Med J (Clin Res Ed). 1984;289:351–353.
Pomara N, Stanley B, Block R, et al. Increased sensitivity of the elderly to the central depressant effects of diazepam. J Clin Psychiatry. 1985;46:185–187.
Swift CG, Ewen JM, Clarke P, et al. Responsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrations. Br J Clin Pharmacol. 1985;20:111–118.
Guthrie S, Cooper RL, Thurman R, et al. Pharmacodynamics and pharmacokinetics of ethanol, diazepam and pentobarbital in young and aged rats. Pharmacol Toxicol. 1987;61:308–312.
Hinrichs JV, Ghoneim MM. Diazepam, behavior, and aging: increased sensitivity or lower baseline performance? Psychopharmacology (Berl). 1987;92:100–105.
Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther. 2004;76:467–479.
Barnhill JG, Greenblatt DJ, Miller LG, et al. Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals. J Pharmacol Exp Ther. 1990;253:1153–1161.
Greenblatt DJ, Laughren TP, Allen MD, et al. Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy. Br J Clin Pharmacol. 1981;11:35–40.
Greenblatt DJ, Divoll M, Abernethy DR, et al. Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab Rev. 1983;14:251–292.
Greenblatt DJ, Harmatz JS, Shader RI. Psychotropic drug prescribing in the United States: extent, costs, and expenditures. J Clin Psychopharmacol. 2011;31:1–3.
Greenblatt DJ, Harmatz JS, Shader RI. Update on psychotropic drug prescribing in the United States: 2014-2015. J Clin Psychopharmacol. 2018;38:1–4.
Rickels K, Schweizer E, Case WG, et al. Long-term therapeutic use of benzodiazepines I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47:899–907.
Substance Nomenclature :
Q3JTX2Q7TU (Diazepam)
Entry Date(s) :
Date Created: 20200426 Date Completed: 20210113 Latest Revision: 20210125
Update Code :
20210301
DOI :
10.1097/JCP.0000000000001213
PMID :
32332456
Opinia redakcyjna

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies